Breast cancer (Tokyo, Japan) · 2026
Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiaoyi, Chen Po-Huang, Chang Wei-Cheng, Jhou Hong-Jie, Chen Hsin-Yu, Kao Li-Ting, Hsieh Tina Yi-Jin, Dai Ming-Shen, Xiao Na, Lee Cho-Hao
Аннотация
BACKGROUND: Head-to-head randomized trials of CDK4/6 inhibitors are lacking. We emulated a target trial of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer.
METHODS: Using TriNetX (January 2014-March 2025), adults initiating first-line endocrine therapy plus ribociclib or palbociclib underwent 1:1 propensity score matching. The primary outcome was all-cause mortality. The co-primary calendar-restricted survival analysis applied a year-level restriction beginning January 1, 2017, the calendar year of ribociclib market entry.
RESULTS: The prescription-confirmed cohort comprised 11,685 patients; 4394 were matched (2197 per group; mean age 60.2 years; 97.9% female). In the whole-period co-primary analysis, ribociclib was associated with longer overall survival (hazard ratio [HR] 0.82, 95% CI 0.73-0.92) and a 48-month restricted mean survival difference of 1.7 months (95% CI 0.5-2.8). The all-initiator analysis removing the second-prescription requirement yielded HR 0.86 (95% CI 0.75-0.99) but did not restrict calendar time. The separately matched calendar-restricted co-primary analysis (from 2017; 1924 per arm) yielded HR 0.90 (95% CI 0.82-0.99); residual temporal confounding could favor ribociclib. Exploratory analyses showed lower cause-specific hazards of recorded hematologic events (neutropenia HR 0.69, thrombocytopenia HR 0.52, anemia HR 0.80) and higher hazards of recorded QT prolongation and dermatologic events (HR 1.61 and 1.41); no detectable differences were observed for healthcare utilization or severe infections.
CONCLUSIONS: Both co-primary analyses showed an association with longer overall survival for ribociclib, with attenuation in the calendar-restricted analysis (HR 0.90, 95% CI 0.82-0.99). These findings are hypothesis-generating, not evidence of superiority, and require randomized confirmation.
METHODS: Using TriNetX (January 2014-March 2025), adults initiating first-line endocrine therapy plus ribociclib or palbociclib underwent 1:1 propensity score matching. The primary outcome was all-cause mortality. The co-primary calendar-restricted survival analysis applied a year-level restriction beginning January 1, 2017, the calendar year of ribociclib market entry.
RESULTS: The prescription-confirmed cohort comprised 11,685 patients; 4394 were matched (2197 per group; mean age 60.2 years; 97.9% female). In the whole-period co-primary analysis, ribociclib was associated with longer overall survival (hazard ratio [HR] 0.82, 95% CI 0.73-0.92) and a 48-month restricted mean survival difference of 1.7 months (95% CI 0.5-2.8). The all-initiator analysis removing the second-prescription requirement yielded HR 0.86 (95% CI 0.75-0.99) but did not restrict calendar time. The separately matched calendar-restricted co-primary analysis (from 2017; 1924 per arm) yielded HR 0.90 (95% CI 0.82-0.99); residual temporal confounding could favor ribociclib. Exploratory analyses showed lower cause-specific hazards of recorded hematologic events (neutropenia HR 0.69, thrombocytopenia HR 0.52, anemia HR 0.80) and higher hazards of recorded QT prolongation and dermatologic events (HR 1.61 and 1.41); no detectable differences were observed for healthcare utilization or severe infections.
CONCLUSIONS: Both co-primary analyses showed an association with longer overall survival for ribociclib, with attenuation in the calendar-restricted analysis (HR 0.90, 95% CI 0.82-0.99). These findings are hypothesis-generating, not evidence of superiority, and require randomized confirmation.